nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—YES1—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00427	0.00427	CbGpPWpGaD
Dasatinib—ERBB3—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00425	0.00425	CbGpPWpGaD
Dasatinib—PDGFRB—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00425	0.00425	CbGpPWpGaD
Dasatinib—PDGFRB—GAB1 signalosome—FRS2—nasal cavity cancer	0.00421	0.00421	CbGpPWpGaD
Dasatinib—FYN—PI-3K cascade—FRS2—nasal cavity cancer	0.00419	0.00419	CbGpPWpGaD
Dasatinib—JAK2—Insulin receptor signalling cascade—FRS2—nasal cavity cancer	0.00419	0.00419	CbGpPWpGaD
Dasatinib—JAK2—IGF1R signaling cascade—FRS2—nasal cavity cancer	0.00419	0.00419	CbGpPWpGaD
Dasatinib—PDGFRB—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00412	0.00412	CbGpPWpGaD
Dasatinib—BLK—B Cell Activation—FRS2—nasal cavity cancer	0.00409	0.00409	CbGpPWpGaD
Dasatinib—FYN—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00409	0.00409	CbGpPWpGaD
Dasatinib—FYN—GAB1 signalosome—FRS2—nasal cavity cancer	0.00406	0.00406	CbGpPWpGaD
Dasatinib—ERBB3—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00405	0.00405	CbGpPWpGaD
Dasatinib—ERBB3—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00405	0.00405	CbGpPWpGaD
Dasatinib—ERBB3—DAP12 interactions—FRS2—nasal cavity cancer	0.00405	0.00405	CbGpPWpGaD
Dasatinib—LYN—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00403	0.00403	CbGpPWpGaD
Dasatinib—ERBB3—Signaling by EGFR—FRS2—nasal cavity cancer	0.00402	0.00402	CbGpPWpGaD
Dasatinib—ERBB3—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00398	0.00398	CbGpPWpGaD
Dasatinib—FYN—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00397	0.00397	CbGpPWpGaD
Dasatinib—ERBB3—Signaling by PDGF—FRS2—nasal cavity cancer	0.00396	0.00396	CbGpPWpGaD
Dasatinib—TXK—Innate Immune System—FRS2—nasal cavity cancer	0.00394	0.00394	CbGpPWpGaD
Dasatinib—LCK—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00387	0.00387	CbGpPWpGaD
Dasatinib—KIT—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00381	0.00381	CbGpPWpGaD
Dasatinib—YES1—Signaling by ERBB2—FRS2—nasal cavity cancer	0.0038	0.0038	CbGpPWpGaD
Dasatinib—ERBB3—B Cell Activation—FRS2—nasal cavity cancer	0.00375	0.00375	CbGpPWpGaD
Dasatinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00373	0.00373	CbGpPWpGaD
Dasatinib—ABCB1—Allograft Rejection—CXCL11—nasal cavity cancer	0.00369	0.00369	CbGpPWpGaD
Dasatinib—KIT—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00365	0.00365	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00361	0.00361	CbGpPWpGaD
Dasatinib—ERBB3—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00359	0.00359	CbGpPWpGaD
Dasatinib—KIT—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00359	0.00359	CbGpPWpGaD
Dasatinib—LCK—PI-3K cascade—FRS2—nasal cavity cancer	0.00349	0.00349	CbGpPWpGaD
Dasatinib—JAK2—Signaling by Insulin receptor—FRS2—nasal cavity cancer	0.00348	0.00348	CbGpPWpGaD
Dasatinib—PDGFRA—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00345	0.00345	CbGpPWpGaD
Dasatinib—KIT—Downstream signal transduction—FRS2—nasal cavity cancer	0.00343	0.00343	CbGpPWpGaD
Dasatinib—KIT—Signaling by FGFR—FRS2—nasal cavity cancer	0.00341	0.00341	CbGpPWpGaD
Dasatinib—LCK—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00341	0.00341	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling by ERBB4—FRS2—nasal cavity cancer	0.0034	0.0034	CbGpPWpGaD
Dasatinib—KIT—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00339	0.00339	CbGpPWpGaD
Dasatinib—LCK—GAB1 signalosome—FRS2—nasal cavity cancer	0.00338	0.00338	CbGpPWpGaD
Dasatinib—KIT—DAP12 signaling—FRS2—nasal cavity cancer	0.00338	0.00338	CbGpPWpGaD
Dasatinib—KIT—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00333	0.00333	CbGpPWpGaD
Dasatinib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.0033	0.0033	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00325	0.00325	CbGpPWpGaD
Dasatinib—PDGFRA—Downstream signal transduction—FRS2—nasal cavity cancer	0.00325	0.00325	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling by FGFR—FRS2—nasal cavity cancer	0.00323	0.00323	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00321	0.00321	CbGpPWpGaD
Dasatinib—PDGFRA—DAP12 signaling—FRS2—nasal cavity cancer	0.0032	0.0032	CbGpPWpGaD
Dasatinib—LYN—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00318	0.00318	CbGpPWpGaD
Dasatinib—KIT—DAP12 interactions—FRS2—nasal cavity cancer	0.00318	0.00318	CbGpPWpGaD
Dasatinib—KIT—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00318	0.00318	CbGpPWpGaD
Dasatinib—KIT—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00318	0.00318	CbGpPWpGaD
Dasatinib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00315	0.00315	CbGpPWpGaD
Dasatinib—KIT—Signaling by EGFR—FRS2—nasal cavity cancer	0.00315	0.00315	CbGpPWpGaD
Dasatinib—FYN—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00313	0.00313	CbGpPWpGaD
Dasatinib—RIPK2—Signaling by NGF—FRS2—nasal cavity cancer	0.00313	0.00313	CbGpPWpGaD
Dasatinib—KIT—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00312	0.00312	CbGpPWpGaD
Dasatinib—PDGFRB—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00311	0.00311	CbGpPWpGaD
Dasatinib—KIT—Signaling by PDGF—FRS2—nasal cavity cancer	0.00311	0.00311	CbGpPWpGaD
Dasatinib—FYN—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00308	0.00308	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00306	0.00306	CbGpPWpGaD
Dasatinib—PDGFRA—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00301	0.00301	CbGpPWpGaD
Dasatinib—PDGFRA—DAP12 interactions—FRS2—nasal cavity cancer	0.00301	0.00301	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00301	0.00301	CbGpPWpGaD
Dasatinib—FYN—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.003	0.003	CbGpPWpGaD
Dasatinib—SRC—GAB1 signalosome—FRS2—nasal cavity cancer	0.00299	0.00299	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling by EGFR—FRS2—nasal cavity cancer	0.00298	0.00298	CbGpPWpGaD
Dasatinib—JAK2—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00298	0.00298	CbGpPWpGaD
Dasatinib—MAPK14—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00297	0.00297	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00295	0.00295	CbGpPWpGaD
Dasatinib—FYN—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00295	0.00295	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling by PDGF—FRS2—nasal cavity cancer	0.00294	0.00294	CbGpPWpGaD
Dasatinib—KIT—B Cell Activation—FRS2—nasal cavity cancer	0.00294	0.00294	CbGpPWpGaD
Dasatinib—JAK2—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00293	0.00293	CbGpPWpGaD
Dasatinib—PDGFRB—Downstream signal transduction—FRS2—nasal cavity cancer	0.00292	0.00292	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling by FGFR—FRS2—nasal cavity cancer	0.00291	0.00291	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00289	0.00289	CbGpPWpGaD
Dasatinib—PDGFRB—DAP12 signaling—FRS2—nasal cavity cancer	0.00288	0.00288	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling by NGF—FRS2—nasal cavity cancer	0.00287	0.00287	CbGpPWpGaD
Dasatinib—JAK2—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00285	0.00285	CbGpPWpGaD
Dasatinib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00284	0.00284	CbGpPWpGaD
Dasatinib—FYN—Downstream signal transduction—FRS2—nasal cavity cancer	0.00282	0.00282	CbGpPWpGaD
Dasatinib—KIT—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00281	0.00281	CbGpPWpGaD
Dasatinib—JAK2—Signaling by ERBB4—FRS2—nasal cavity cancer	0.0028	0.0028	CbGpPWpGaD
Dasatinib—FYN—Signaling by FGFR—FRS2—nasal cavity cancer	0.0028	0.0028	CbGpPWpGaD
Dasatinib—FYN—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00279	0.00279	CbGpPWpGaD
Dasatinib—PDGFRA—B Cell Activation—FRS2—nasal cavity cancer	0.00278	0.00278	CbGpPWpGaD
Dasatinib—FYN—DAP12 signaling—FRS2—nasal cavity cancer	0.00278	0.00278	CbGpPWpGaD
Dasatinib—ERBB3—Signaling by NGF—FRS2—nasal cavity cancer	0.00276	0.00276	CbGpPWpGaD
Dasatinib—FYN—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00274	0.00274	CbGpPWpGaD
Dasatinib—PDGFRB—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00271	0.00271	CbGpPWpGaD
Dasatinib—PDGFRB—DAP12 interactions—FRS2—nasal cavity cancer	0.00271	0.00271	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00271	0.00271	CbGpPWpGaD
Dasatinib—SRMS—Immune System—FRS2—nasal cavity cancer	0.0027	0.0027	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling by EGFR—FRS2—nasal cavity cancer	0.00269	0.00269	CbGpPWpGaD
Dasatinib—JAK2—Downstream signal transduction—FRS2—nasal cavity cancer	0.00268	0.00268	CbGpPWpGaD
Dasatinib—JAK2—Signaling by FGFR—FRS2—nasal cavity cancer	0.00267	0.00267	CbGpPWpGaD
Dasatinib—PDGFRA—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00266	0.00266	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00266	0.00266	CbGpPWpGaD
Dasatinib—LYN—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00265	0.00265	CbGpPWpGaD
Dasatinib—JAK2—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00265	0.00265	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling by PDGF—FRS2—nasal cavity cancer	0.00265	0.00265	CbGpPWpGaD
Dasatinib—JAK2—DAP12 signaling—FRS2—nasal cavity cancer	0.00264	0.00264	CbGpPWpGaD
Dasatinib—FYN—DAP12 interactions—FRS2—nasal cavity cancer	0.00261	0.00261	CbGpPWpGaD
Dasatinib—FYN—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00261	0.00261	CbGpPWpGaD
Dasatinib—FYN—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00261	0.00261	CbGpPWpGaD
Dasatinib—LCK—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00261	0.00261	CbGpPWpGaD
Dasatinib—FYN—Signaling by EGFR—FRS2—nasal cavity cancer	0.00259	0.00259	CbGpPWpGaD
Dasatinib—FYN—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00257	0.00257	CbGpPWpGaD
Dasatinib—FYN—Signaling by PDGF—FRS2—nasal cavity cancer	0.00255	0.00255	CbGpPWpGaD
Dasatinib—PDGFRB—B Cell Activation—FRS2—nasal cavity cancer	0.00251	0.00251	CbGpPWpGaD
Dasatinib—LCK—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.0025	0.0025	CbGpPWpGaD
Dasatinib—JAK2—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00248	0.00248	CbGpPWpGaD
Dasatinib—JAK2—DAP12 interactions—FRS2—nasal cavity cancer	0.00248	0.00248	CbGpPWpGaD
Dasatinib—JAK2—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00248	0.00248	CbGpPWpGaD
Dasatinib—JAK2—Signaling by EGFR—FRS2—nasal cavity cancer	0.00246	0.00246	CbGpPWpGaD
Dasatinib—LCK—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00246	0.00246	CbGpPWpGaD
Dasatinib—LYN—B Cell Activation—FRS2—nasal cavity cancer	0.00246	0.00246	CbGpPWpGaD
Dasatinib—JAK2—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00244	0.00244	CbGpPWpGaD
Dasatinib—JAK2—Signaling by PDGF—FRS2—nasal cavity cancer	0.00243	0.00243	CbGpPWpGaD
Dasatinib—FYN—B Cell Activation—FRS2—nasal cavity cancer	0.00242	0.00242	CbGpPWpGaD
Dasatinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0024	0.0024	CbGpPWpGaD
Dasatinib—CSK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00237	0.00237	CbGpPWpGaD
Dasatinib—LCK—Downstream signal transduction—FRS2—nasal cavity cancer	0.00235	0.00235	CbGpPWpGaD
Dasatinib—LCK—Signaling by FGFR—FRS2—nasal cavity cancer	0.00233	0.00233	CbGpPWpGaD
Dasatinib—LCK—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00232	0.00232	CbGpPWpGaD
Dasatinib—FYN—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00231	0.00231	CbGpPWpGaD
Dasatinib—LCK—DAP12 signaling—FRS2—nasal cavity cancer	0.00231	0.00231	CbGpPWpGaD
Dasatinib—SRC—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00231	0.00231	CbGpPWpGaD
Dasatinib—TXK—Immune System—FRS2—nasal cavity cancer	0.00229	0.00229	CbGpPWpGaD
Dasatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00228	0.00228	CbGpPWpGaD
Dasatinib—SRC—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00227	0.00227	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00224	0.00224	CbGpPWpGaD
Dasatinib—MAPK14—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00223	0.00223	CbGpPWpGaD
Dasatinib—JAK2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0022	0.0022	CbGpPWpGaD
Dasatinib—LCK—DAP12 interactions—FRS2—nasal cavity cancer	0.00217	0.00217	CbGpPWpGaD
Dasatinib—LCK—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00217	0.00217	CbGpPWpGaD
Dasatinib—LCK—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00217	0.00217	CbGpPWpGaD
Dasatinib—KIT—Signaling by NGF—FRS2—nasal cavity cancer	0.00216	0.00216	CbGpPWpGaD
Dasatinib—LCK—Signaling by EGFR—FRS2—nasal cavity cancer	0.00216	0.00216	CbGpPWpGaD
Dasatinib—LCK—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00214	0.00214	CbGpPWpGaD
Dasatinib—LCK—Signaling by PDGF—FRS2—nasal cavity cancer	0.00213	0.00213	CbGpPWpGaD
Dasatinib—SRC—Downstream signal transduction—FRS2—nasal cavity cancer	0.00208	0.00208	CbGpPWpGaD
Dasatinib—BTK—Innate Immune System—FRS2—nasal cavity cancer	0.00207	0.00207	CbGpPWpGaD
Dasatinib—SRC—Signaling by FGFR—FRS2—nasal cavity cancer	0.00207	0.00207	CbGpPWpGaD
Dasatinib—SRC—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00206	0.00206	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling by NGF—FRS2—nasal cavity cancer	0.00205	0.00205	CbGpPWpGaD
Dasatinib—LCK—B Cell Activation—FRS2—nasal cavity cancer	0.00201	0.00201	CbGpPWpGaD
Dasatinib—BTK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00199	0.00199	CbGpPWpGaD
Dasatinib—LCK—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00193	0.00193	CbGpPWpGaD
Dasatinib—SRC—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00193	0.00193	CbGpPWpGaD
Dasatinib—SRC—Signaling by EGFR—FRS2—nasal cavity cancer	0.00191	0.00191	CbGpPWpGaD
Dasatinib—HCK—Innate Immune System—FRS2—nasal cavity cancer	0.0019	0.0019	CbGpPWpGaD
Dasatinib—SRC—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00189	0.00189	CbGpPWpGaD
Dasatinib—SRC—Signaling by PDGF—FRS2—nasal cavity cancer	0.00188	0.00188	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling by NGF—FRS2—nasal cavity cancer	0.00185	0.00185	CbGpPWpGaD
Dasatinib—RIPK2—Innate Immune System—FRS2—nasal cavity cancer	0.00179	0.00179	CbGpPWpGaD
Dasatinib—FYN—Signaling by NGF—FRS2—nasal cavity cancer	0.00178	0.00178	CbGpPWpGaD
Dasatinib—RIPK2—Adaptive Immune System—FRS2—nasal cavity cancer	0.00172	0.00172	CbGpPWpGaD
Dasatinib—MAPK14—Signaling by NGF—FRS2—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Dasatinib—FGR—Innate Immune System—FRS2—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Dasatinib—SRC—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Dasatinib—JAK2—Signaling by NGF—FRS2—nasal cavity cancer	0.00169	0.00169	CbGpPWpGaD
Dasatinib—BLK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00165	0.00165	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—CXCL11—nasal cavity cancer	0.00158	0.00158	CbGpPWpGaD
Dasatinib—ERBB3—Innate Immune System—FRS2—nasal cavity cancer	0.00158	0.00158	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00153	0.00153	CbGpPWpGaD
Dasatinib—ERBB3—Adaptive Immune System—FRS2—nasal cavity cancer	0.00151	0.00151	CbGpPWpGaD
Dasatinib—LCK—Signaling by NGF—FRS2—nasal cavity cancer	0.00148	0.00148	CbGpPWpGaD
Dasatinib—CSK—Immune System—FRS2—nasal cavity cancer	0.00144	0.00144	CbGpPWpGaD
Dasatinib—STAT5B—Immune System—FRS2—nasal cavity cancer	0.00139	0.00139	CbGpPWpGaD
Dasatinib—YES1—Innate Immune System—FRS2—nasal cavity cancer	0.00138	0.00138	CbGpPWpGaD
Dasatinib—CSK—Disease—FRS2—nasal cavity cancer	0.00133	0.00133	CbGpPWpGaD
Dasatinib—YES1—Adaptive Immune System—FRS2—nasal cavity cancer	0.00133	0.00133	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—FRS2—nasal cavity cancer	0.00132	0.00132	CbGpPWpGaD
Dasatinib—SRC—Signaling by NGF—FRS2—nasal cavity cancer	0.00131	0.00131	CbGpPWpGaD
Dasatinib—STAT5B—Disease—FRS2—nasal cavity cancer	0.00129	0.00129	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—FRS2—nasal cavity cancer	0.00124	0.00124	CbGpPWpGaD
Dasatinib—KIT—Innate Immune System—FRS2—nasal cavity cancer	0.00123	0.00123	CbGpPWpGaD
Dasatinib—BTK—Immune System—FRS2—nasal cavity cancer	0.0012	0.0012	CbGpPWpGaD
Dasatinib—KIT—Adaptive Immune System—FRS2—nasal cavity cancer	0.00119	0.00119	CbGpPWpGaD
Dasatinib—PDGFRA—Innate Immune System—FRS2—nasal cavity cancer	0.00117	0.00117	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00115	0.00115	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00114	0.00114	CbGpPWpGaD
Dasatinib—PDGFRA—Adaptive Immune System—FRS2—nasal cavity cancer	0.00112	0.00112	CbGpPWpGaD
Dasatinib—HCK—Immune System—FRS2—nasal cavity cancer	0.0011	0.0011	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—FRS2—nasal cavity cancer	0.00105	0.00105	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—CXCL11—nasal cavity cancer	0.00104	0.00104	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00104	0.00104	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—FRS2—nasal cavity cancer	0.00104	0.00104	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—FRS2—nasal cavity cancer	0.00103	0.00103	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—FRS2—nasal cavity cancer	0.00103	0.00103	CbGpPWpGaD
Dasatinib—HCK—Disease—FRS2—nasal cavity cancer	0.00102	0.00102	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—FRS2—nasal cavity cancer	0.00101	0.00101	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—FRS2—nasal cavity cancer	0.00101	0.00101	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00101	0.00101	CbGpPWpGaD
Dasatinib—BLK—Immune System—FRS2—nasal cavity cancer	0.001	0.001	CbGpPWpGaD
Dasatinib—FGR—Immune System—FRS2—nasal cavity cancer	0.000998	0.000998	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—FRS2—nasal cavity cancer	0.00099	0.00099	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—FRS2—nasal cavity cancer	0.000977	0.000977	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—FRS2—nasal cavity cancer	0.000975	0.000975	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—FRS2—nasal cavity cancer	0.000965	0.000965	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—FRS2—nasal cavity cancer	0.000931	0.000931	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—FRS2—nasal cavity cancer	0.000917	0.000917	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—FRS2—nasal cavity cancer	0.000901	0.000901	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000883	0.000883	CbGpPWpGaD
Dasatinib—ERBB3—Disease—FRS2—nasal cavity cancer	0.000847	0.000847	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—FRS2—nasal cavity cancer	0.000845	0.000845	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—FRS2—nasal cavity cancer	0.000811	0.000811	CbGpPWpGaD
Dasatinib—YES1—Immune System—FRS2—nasal cavity cancer	0.000805	0.000805	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CXCL11—nasal cavity cancer	0.000789	0.000789	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—FRS2—nasal cavity cancer	0.000748	0.000748	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CXCL11—nasal cavity cancer	0.000747	0.000747	CbGpPWpGaD
Dasatinib—KIT—Immune System—FRS2—nasal cavity cancer	0.000719	0.000719	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—FRS2—nasal cavity cancer	0.000718	0.000718	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—FRS2—nasal cavity cancer	0.000681	0.000681	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—FRS2—nasal cavity cancer	0.000673	0.000673	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CXCL11—nasal cavity cancer	0.000673	0.000673	CbGpPWpGaD
Dasatinib—KIT—Disease—FRS2—nasal cavity cancer	0.000664	0.000664	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CXCL11—nasal cavity cancer	0.000659	0.000659	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CXCL11—nasal cavity cancer	0.000649	0.000649	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—FRS2—nasal cavity cancer	0.000629	0.000629	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CXCL11—nasal cavity cancer	0.000624	0.000624	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CXCL11—nasal cavity cancer	0.000616	0.000616	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—FRS2—nasal cavity cancer	0.000615	0.000615	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—FRS2—nasal cavity cancer	0.000613	0.000613	CbGpPWpGaD
Dasatinib—LYN—Immune System—FRS2—nasal cavity cancer	0.0006	0.0006	CbGpPWpGaD
Dasatinib—ABL1—Immune System—FRS2—nasal cavity cancer	0.000598	0.000598	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—FRS2—nasal cavity cancer	0.000593	0.000593	CbGpPWpGaD
Dasatinib—FYN—Immune System—FRS2—nasal cavity cancer	0.000591	0.000591	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—FRS2—nasal cavity cancer	0.000569	0.000569	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—FRS2—nasal cavity cancer	0.000566	0.000566	CbGpPWpGaD
Dasatinib—JAK2—Immune System—FRS2—nasal cavity cancer	0.000562	0.000562	CbGpPWpGaD
Dasatinib—FYN—Disease—FRS2—nasal cavity cancer	0.000546	0.000546	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL11—nasal cavity cancer	0.00054	0.00054	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—FRS2—nasal cavity cancer	0.000521	0.000521	CbGpPWpGaD
Dasatinib—JAK2—Disease—FRS2—nasal cavity cancer	0.000519	0.000519	CbGpPWpGaD
Dasatinib—LCK—Immune System—FRS2—nasal cavity cancer	0.000492	0.000492	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL11—nasal cavity cancer	0.000478	0.000478	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—FRS2—nasal cavity cancer	0.000465	0.000465	CbGpPWpGaD
Dasatinib—LCK—Disease—FRS2—nasal cavity cancer	0.000454	0.000454	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—FRS2—nasal cavity cancer	0.00044	0.00044	CbGpPWpGaD
Dasatinib—SRC—Immune System—FRS2—nasal cavity cancer	0.000436	0.000436	CbGpPWpGaD
Dasatinib—SRC—Disease—FRS2—nasal cavity cancer	0.000402	0.000402	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—FRS2—nasal cavity cancer	0.000397	0.000397	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—FRS2—nasal cavity cancer	0.000388	0.000388	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—FRS2—nasal cavity cancer	0.000382	0.000382	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—FRS2—nasal cavity cancer	0.000368	0.000368	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—FRS2—nasal cavity cancer	0.000363	0.000363	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FRS2—nasal cavity cancer	0.000318	0.000318	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FRS2—nasal cavity cancer	0.000282	0.000282	CbGpPWpGaD
